Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans.
The isothiocyanate sulforaphane [SF; 1-isothiocyanato-4(R)-methylsulfinylbutane] is abundant in broccoli sprouts in the form of its glucosinolate precursor (glucoraphanin). SF is powerfully bactericidal against Helicobacter pylori infections, which are strongly associated with the worldwide pandemic of gastric cancer. Oral treatment with SF-rich broccoli sprouts of C57BL/6 female mice infected with H. pylori Sydney strain 1 and maintained on a high-salt (7.5% NaCl) diet reduced gastric bacterial colonization, attenuated mucosal expression of tumor necrosis factor-alpha and interleukin-1beta, mitigated corpus inflammation, and prevented expression of high salt-induced gastric corpus atrophy. This therapeutic effect was not observed in mice in which the nrf2 gene was deleted, strongly implicating the important role of Nrf2-dependent antioxidant and anti-inflammatory proteins in SF-dependent protection. Forty-eight H. pylori-infected patients were randomly assigned to feeding of broccoli sprouts (70 g/d; containing 420 micromol of SF precursor) for 8 weeks or to consumption of an equal weight of alfalfa sprouts (not containing SF) as placebo. Intervention with broccoli sprouts, but not with placebo, decreased the levels of urease measured by the urea breath test and H. pylori stool antigen (both biomarkers of H. pylori colonization) and serum pepsinogens I and II (biomarkers of gastric inflammation). Values recovered to their original levels 2 months after treatment was discontinued. Daily intake of sulforaphane-rich broccoli sprouts for 2 months reduces H. pylori colonization in mice and improves the sequelae of infection in infected mice and in humans. This treatment seems to enhance chemoprotection of the gastric mucosa against H. pylori-induced oxidative stress.
Division of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba-Ken, Tokyo, Japan. ayanaka@rs.noda.tus.ac.jp
Akinori
A
Yanaka
Jed W
JW
Fahey
Atsushi
A
Fukumoto
Mari
M
Nakayama
Souta
S
Inoue
Songhua
S
Zhang
Masafumi
M
Tauchi
Hideo
H
Suzuki
Ichinosuke
I
Hyodo
Masayuki
M
Yamamoto
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000032:analysis; D001937:Brassica / Q000737:chemistry; D005243:Feces; D005260:Female; D005756:Gastritis / Q000178:diet therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications / Q000178:diet therapy*; D016480:Helicobacter pylori; D006801:Humans; D017879:Isothiocyanates; D000455:Medicago sativa; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D051267:NF-E2-Related Factor 2 / Q000235:genetics; D020116:Pepsinogen A / Q000097:blood; D008517:Phytotherapy / Q000379:methods*; D013454:Sulfoxides; D013861:Thiocyanates / Q000494:pharmacology; D014510:Urease / Q000032:analysis
D016588:Anticarcinogenic Agents; D000942:Antigens, Bacterial; D017879:Isothiocyanates; D051267:NF-E2-Related Factor 2; D013454:Sulfoxides; D013861:Thiocyanates; D020116:Pepsinogen A; D014510:Urease; C016766:sulforaphane